Revolutionary Wormwood Allergy Vaccine Enters Phase 2 Clinical Trials

A new vaccine for wormwood allergies has moved into the second phase of clinical trials. Developers describe it as the world’s first recombinant ragweed pollen vaccine to reach this stage. The treatment could offer faster relief than traditional methods, requiring just four injections over three weeks instead of months or years of therapy. The first round of human trials confirmed the vaccine’s safety and tolerance. Participants showed no adverse effects, and their IgG4 immunoglobulin levels rose by 20 to 30 times within 50 days. Normally, such results take a full year of allergen-specific immunotherapy to achieve.

The next phase will focus on quality and safety assessments. Only patients with a confirmed wormwood allergy—verified through lab tests and medical history—can take part. The study follows a double-blind approach, meaning neither doctors nor participants will know who receives the vaccine or a placebo. If this stage succeeds, the vaccine could move to mass production in two to three years. Its rapid injection schedule contrasts sharply with existing treatments, which often span three months to a year.

The vaccine’s progress marks a potential breakthrough for allergy sufferers. With faster treatment times and strong early results, it may soon offer an alternative to lengthy immunotherapy. Final approval and production timelines depend on the outcome of the current trials.